Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Sponsor
Damanhour University
Study ID
NCT06313008
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
  • Vildagliptin 50 MG — DRUG
    eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).

Study Details

We compared the cardioprotective effects of empagliflozin, an SGLT2 inhibitor, with those of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, focusing on various inflammatory biomarkers lipid profile, and cardiac function, in patients with type 2 diabetes mellitus (T2DM).

Key Dates

Start date
Aug 10, 2023
Status verified
Nov 2024
Primary completion
Sep 30, 2024
Completion
Oct 10, 2024

Study Design

Enrollment
120 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    Eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).
  • Experimental: Vildagliptin
    60 patients recieved vildagliptin as add-on group (vildagliptin 50 mg/day as the initial dose).

Primary Outcome Measure

LVEF % [ Time Frame: 6 months ]

Related Studies